fda compounding semaglutide warning letters october 2025 Sends to More Than 50 GLP-1 Compounders and Manufacturers Novo Nordisk Calls for FDA

In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 diabetes and led to an average of up to 36.6 pounds of weight loss, according to drugmaker Eli Lilly

Retatrutide targets three hormones instead of one , so the buzz is real-and so is the need for an honest , easy-to-understand rundown

Possible side effects of GLP-1 patches include: Skin irritation or rash Increased heart rate Jitteriness or anxiety Trouble sleeping Nausea Some ingredients act as stimulants and may raise blood pressure or interact with other medications

If confirmed by larger trials, their effectiveness against migraines could soon join this expanding list

Go slowly